{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:37:08Z","timestamp":1792859828231,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.autrev.2026.104149","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:21:43Z","timestamp":1785338503000},"page":"104149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding tumor\u2013associated autoantibodies in liver cancer: Mechanisms, clinical applications, and detection methods"],"prefix":"10.1016","volume":"25","author":[{"given":"Chuyan","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104149_bb0005","doi-asserted-by":"crossref","first-page":"1101324","DOI":"10.3389\/fimmu.2023.1101324","article-title":"Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.autrev.2026.104149_bb0015","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3350\/cmh.2023.0070","article-title":"The latest global burden of liver cancer: a past and present threat","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0025","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.autrev.2026.104149_bb0030","first-page":"1","article-title":"Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J Carcinogen"},{"key":"10.1016\/j.autrev.2026.104149_bb0035","first-page":"1054","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014meta-analytic assessment","volume":"8","author":"Tarao","year":"2019"},{"key":"10.1016\/j.autrev.2026.104149_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"Suresh","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0050","first-page":"S294","article-title":"Epidemiological characteristics and risk factors of hepatocellular carcinoma","volume":"12","author":"Chen","year":"1997"},{"key":"10.1016\/j.autrev.2026.104149_bb0055","first-page":"2029","article-title":"Changing epidemiology of hepatocellular carcinoma in Asia","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.autrev.2026.104149_bb0060","first-page":"143","article-title":"Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People\u2019s Republic of China","volume":"10","author":"Wang","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2026.104149_bb0065","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.21037\/jgo-22-720","article-title":"Anti-OJ antibody-positive anti-synthetase syndrome with repeated arthritis, fever, and recurrent liver cancer: a case report","volume":"13","author":"Gu","year":"2022","journal-title":"J Gastrointes Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0070","doi-asserted-by":"crossref","first-page":"18382","DOI":"10.1038\/s41598-023-45716-w","article-title":"Association of TERT (rs2736098 and rs2736100) genetic variants with elevated risk of hepatocellular carcinoma: a retrospective case-control study","volume":"13","author":"Seif Eldin","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104149_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3701-1-5","article-title":"Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?","volume":"1","author":"Kumar","year":"2011","journal-title":"Cell Biosci"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104149_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2026.104149_bb0085","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(09)70241-4","article-title":"Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009","volume":"10","author":"Poon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.510270140","article-title":"Screening for hepatocellular carcinoma","volume":"27","author":"Collier","year":"1998","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.autrev.2026.104149_bb0095","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/hep.29869","article-title":"Magic mirror on the wall: which is the best biomarker for hepatocellular carcinoma?","volume":"67","author":"Huo","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104149_bb0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2026.104149_bb0105","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00432-015-1943-0","article-title":"Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats","volume":"141","author":"Liu","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.autrev.2026.104149_bb0110","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/MCG.0b013e31827f0d3d","article-title":"The role of imaging in hepatocellular carcinoma: the present and future","volume":"47","author":"Davarpanah","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104149_bb0115","series-title":"Comprehensive Physiology","first-page":"567","article-title":"Liver immunology","author":"Bogdanos","year":"2026"},{"key":"10.1016\/j.autrev.2026.104149_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010212","article-title":"Association of TIM-3 with BCLC stage, serum PD-L1 detection, and response to Transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"12","author":"Tampaki","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.autrev.2026.104149_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2249.2001.01585.x","article-title":"De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma","volume":"125","author":"Zhang","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","article-title":"Goals and targets for personalized therapy for HCC","volume":"13","author":"Couri","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.autrev.2026.104149_bb0135","first-page":"386","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Can"},{"key":"10.1016\/j.autrev.2026.104149_bb0140","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ueg2.12286","article-title":"New concepts in the treatment of hepatocellular carcinoma","volume":"10","author":"Sidali","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104149_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4254\/wjh.v7.i3.406","article-title":"Staging systems for hepatocellular carcinoma: current status and future perspectives","volume":"7","author":"Kinoshita","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0155","first-page":"317","article-title":"Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare, Cancer causes & control","volume":"32","author":"Zhang","year":"2021","journal-title":"CCC"},{"key":"10.1016\/j.autrev.2026.104149_bb0160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1172\/JCI14451","article-title":"Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis","volume":"108","author":"Tan","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104149_bb0165","series-title":"Current concepts in autoimmunity and chronic inflammation","first-page":"161","article-title":"Inefficient clearance of dying cells and autoreactivity","author":"Gaipl","year":"2006"},{"key":"10.1016\/j.autrev.2026.104149_bb0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-065X.2008.00611.x","article-title":"Autoantibodies to tumor-associated antigens: reporters from the immune system","volume":"222","author":"Tan","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104149_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/erm.10.12","article-title":"Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors","volume":"10","author":"Zhang","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.autrev.2026.104149_bb0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pathophys.2008.07.002","article-title":"Autoimmune regulation of genetically determined cell functions in health and disease","volume":"15","author":"Zaichik","year":"2008","journal-title":"Pathophysiology"},{"key":"10.1016\/j.autrev.2026.104149_bb0185","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer; a biological approach. I. The processes of control","volume":"1","author":"Burnet","year":"1957","journal-title":"Br Med J"},{"key":"10.1016\/j.autrev.2026.104149_bb0190","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.2910010305","article-title":"Tumour-specific immunity against spontaneous rat tumours","volume":"1","author":"Baldwin","year":"1966","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bios.2014.09.088","article-title":"Blueprint of quartz crystal microbalance biosensor for early detection of breast cancer through salivary autoantibodies against ATP6AP1","volume":"65","author":"Arif","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.autrev.2026.104149_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2019.111315","article-title":"Autoantibodies as diagnostic and prognostic cancer biomarker: detection techniques and approaches","volume":"139","author":"Yadav","year":"2019","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.autrev.2026.104149_bb0205","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/pr0500814","article-title":"The sentinel within: exploiting the immune system for cancer biomarkers","volume":"4","author":"Anderson","year":"2005","journal-title":"J Proteome Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0210","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s13277-015-4074-y","article-title":"Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma","volume":"37","author":"Zhou","year":"2016","journal-title":"Tumour Biol J Int Soc Oncodevelop Biol Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116139","article-title":"Immunodiagnostic biomarkers for hepatocellular carcinoma (HCC): the first step in detection and treatment","volume":"22","author":"Xing","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.autrev.2006.09.009","article-title":"Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma","volume":"6","author":"Zhang","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104149_bb0225","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-025-56878-8","article-title":"A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104149_bb0230","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12967-024-05787-3","article-title":"Cross-sectional study on the diagnostic significance of plasma exosomal miRNAs in HBV-related hepatocellular carcinoma","volume":"22","author":"Hu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110868","article-title":"Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression","volume":"124","author":"Du","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2026.104149_bb0240","first-page":"2544","article-title":"Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis","volume":"101","author":"Zhang","year":"2021","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.autrev.2026.104149_bb0245","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature03724","article-title":"Cellular and genetic mechanisms of self tolerance and autoimmunity","volume":"435","author":"Goodnow","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104149_bb0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2016.01.017","article-title":"Autoantibody production in Cancer\u2014the humoral immune response toward autologous antigens in Cancer patients","volume":"15","author":"Zaenker","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104149_bb0255","first-page":"1038","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"384","author":"Cacoub","year":"2021"},{"key":"10.1016\/j.autrev.2026.104149_bb0260","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104149_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005792-200001000-00005","article-title":"Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine interne et maladies Infectieuses Sur le virus de l'Hepatite C","volume":"79","author":"Cacoub","year":"2000","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2026.104149_bb0270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N","article-title":"Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma","volume":"71","author":"Imai","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0275","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature09370","article-title":"Inhibition of follicular T-helper cells by CD8+ regulatory T cells is essential for self tolerance","volume":"467","author":"Kim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104149_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13874","article-title":"Thymic microenvironment remodeling in Cancer Cachexia as a determinant of checkpoint inhibitor efficacy and toxicity","volume":"16","author":"Huang","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.autrev.2026.104149_bb0285","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","article-title":"Autoantigen-specific CD4(+) T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104149_bb0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0295","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12885-023-11577-9","article-title":"Identification of DUSP4\/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis","volume":"23","author":"Klemm","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0300","article-title":"Identification of autoantibody based serological marker for early diagnosis of hepatocellular carcinoma by serological proteome analysis combined with protein microarray: 2202","volume":"58","author":"Hong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2026.104149_bb0305","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s10620-013-2941-1","article-title":"Expression of Ku86 and presence of Ku86 antibody as biomarkers of hepatitis B virus related hepatocellular carcinoma","volume":"59","author":"Xu","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0310","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.febslet.2015.06.038","article-title":"miR-1275: a single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma","volume":"589","author":"Fawzy","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.autrev.2026.104149_bb0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2017.05.018","article-title":"Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma","volume":"402","author":"Lu","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2026.104149_bb0320","first-page":"4168","article-title":"Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation","volume":"52","author":"Winter","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0325","article-title":"Association of elevated autoantibody to high expression of GNAS in hepatocellular carcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2026.104149_bb0330","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/2767-9764.CRC-23-0289","article-title":"Cancer relevance of circulating antibodies against LINE-1 antigens in humans","volume":"3","author":"Vylegzhanina","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.autrev.2026.104149_bb0335","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5448","article-title":"Serum BRD2 autoantibody in hepatocellular carcinoma and its detection using mimotope peptide-conjugated BSA","volume":"61","author":"Heo","year":"2022","journal-title":"Int J Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0340","first-page":"5471","article-title":"Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients","volume":"59","author":"Bei","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0345","first-page":"179","article-title":"Simultaneous determination of \u03b1-fetoprotein immune complexes and \u03b1-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays","volume":"23","author":"Sheng","year":"2009"},{"key":"10.1016\/j.autrev.2026.104149_bb0350","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.autrev.2026.104149_bb0355","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ceb.2004.09.011","article-title":"Death by design: apoptosis, necrosis and autophagy","volume":"16","author":"Edinger","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.autrev.2026.104149_bb0360","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10495-010-0472-1","article-title":"Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells","volume":"15","author":"Peter","year":"2010","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"10.1016\/j.autrev.2026.104149_bb0365","doi-asserted-by":"crossref","first-page":"1992104","DOI":"10.1080\/2162402X.2021.1992104","article-title":"Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma","volume":"10","author":"Li","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2026.104149_bb0370","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86591.3","article-title":"An unexpected role of neutrophils in clearing apoptotic hepatocytes in vivo","volume":"12","author":"Cao","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.autrev.2026.104149_bb0375","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.abn1034","article-title":"Decoding the autoantibody reactome","volume":"383","author":"Jaycox","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104149_bb0380","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1568-9972(03)00047-8","article-title":"Autoimmunity seen through the SEREX-scope","volume":"2","author":"Krebs","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104149_bb0385","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.1997.15.11.3363","article-title":"High-titer HER-2\/neu protein-specific antibody can be detected in patients with early-stage breast cancer","volume":"15","author":"Disis","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0390","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fc\u03b3 receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104149_bb0395","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1172\/JCI130029","article-title":"Functional diversification of IgGs through fc glycosylation","volume":"129","author":"Wang","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104149_bb0400","doi-asserted-by":"crossref","first-page":"18936","DOI":"10.1073\/pnas.0803943105","article-title":"Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression","volume":"105","author":"Hedlund","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104149_bb0405","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/0008-5472.CAN-10-4102","article-title":"Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer","volume":"71","author":"Padler-Karavani","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0410","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1073\/pnas.1417508112","article-title":"A red meat-derived glycan promotes inflammation and cancer progression","volume":"112","author":"Samraj","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104149_bb0415","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/15321819.2025.2480368","article-title":"High prevalence of antinuclear antibodies in hepatitis C related hepatocellular carcinoma","volume":"46","author":"El-Far","year":"2025","journal-title":"J Immunoassay Immunochem"},{"key":"10.1016\/j.autrev.2026.104149_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087067","article-title":"Autoreactivity against denatured type III collagen is significantly decreased in serum from patients with Cancer compared to healthy controls","volume":"24","author":"Jensen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0425","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00262-021-03106-z","article-title":"Anti-PD1\/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy","volume":"71","author":"Tan","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2026.104149_bb0430","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","article-title":"International liver Cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma","volume":"160","author":"Singal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104149_bb0435","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3748\/wjg.v30.i8.799","article-title":"Management of autoimmune hepatitis induced by hepatitis delta virus","volume":"30","author":"Gigi","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104149_bb0440","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0445","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000531773","article-title":"Autoimmune hepatitis induced by Hepatitis Delta virus: a conundrum","volume":"31","author":"Cardoso","year":"2024","journal-title":"GE Port J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104149_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100872","article-title":"Screening of Cancer-specific biomarkers for hepatitis B-related hepatocellular carcinoma based on a proteome microarray","volume":"23","author":"Hao","year":"2024","journal-title":"Mol Cell Proteomics MCP"},{"key":"10.1016\/j.autrev.2026.104149_bb0455","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh-24-134","article-title":"Autoantibody positivity in chronic hepatitis C pre- and post-direct-acting antiviral therapy: a prospective multicenter south Korean study","volume":"10","author":"Choi","year":"2025","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0460","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ebiom.2015.04.007","article-title":"Serum DHCR24 auto-antibody as a new biomarker for progression of hepatitis C","volume":"2","author":"Ezzikouri","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2026.104149_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.120037","article-title":"Prevalence and heterogeneity of antinuclear antibody patterns in adult Italian patients with autoimmune liver diseases: our experience","volume":"566","author":"Gambino","year":"2025","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2026.104149_bb0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-2143(98)90096-8","article-title":"Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury","volume":"131","author":"Biron","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0475","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s42255-022-00711-9","article-title":"Cytosolic aldose metabolism contributes to progression from cirrhosis to hepatocarcinogenesis","volume":"5","author":"Oaks","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.autrev.2026.104149_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103112","article-title":"mTOR-dependent loss of PON1 secretion and antiphospholipid autoantibody production underlie autoimmunity-mediated cirrhosis in transaldolase deficiency","volume":"140","author":"Winans","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104149_bb0485","article-title":"Serum Anti-14-3-3 zeta autoantibody as a biomarker for predicting Hepatocarcinogenesis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043721","article-title":"Autoantibodies to PAX5, PTCH1, and GNA11 as serological biomarkers in the detection of hepatocellular carcinoma in Hispanic Americans","volume":"24","author":"Qiu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101388","article-title":"Development of autoantibody signatures for common cancers","volume":"47","author":"Kobayashi","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040813","article-title":"Anti-Cancer auto-antibodies: roles, applications and open issues","volume":"13","author":"de Jonge","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.autrev.2026.104149_bb0505","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acs.jproteome.3c00579","article-title":"hccTAAb atlas: an integrated knowledge database for tumor-associated autoantibodies in hepatocellular carcinoma","volume":"23","author":"Li","year":"2024","journal-title":"J Proteome Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0510","article-title":"Autoantibody to GNAS in early detection of hepatocellular carcinoma: a large-scale sample study combined with verification in serial sera from HCC patients","volume":"10","author":"Wang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.104149_bb0515","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.advms.2025.01.004","article-title":"Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma","volume":"70","author":"Wang","year":"2025","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0520","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/sj.bjc.6602716","article-title":"TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma","volume":"93","author":"Yin","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0525","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021887","article-title":"Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: evidence from a meta-analysis","volume":"99","author":"Chang","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2026.104149_bb0530","article-title":"Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma","volume":"12","author":"Li","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.autrev.2026.104149_bb0535","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/1878-0261.13371","article-title":"Human proteome microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma","volume":"17","author":"Yang","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0540","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cca.2021.10.037","article-title":"Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma","volume":"523","author":"Yang","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2026.104149_bb0545","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3892\/ol.2022.13487","article-title":"Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: a prospective multi-institutional study","volume":"24","author":"Okada","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.autrev.2026.104149_bb0550","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cas.15217","article-title":"A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system","volume":"113","author":"Wu","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232247","article-title":"Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma","volume":"15","author":"Welberry","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104149_bb0560","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-025-09188-4","article-title":"Humoral determinants of checkpoint immunotherapy","volume":"644","author":"Dai","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104149_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/cells11203227","article-title":"Autoantibody against tumor-associated antigens as diagnostic biomarkers in Hispanic patients with hepatocellular carcinoma","volume":"11","author":"Ma","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104149_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117727","article-title":"Proteome microarray identifies autoantibody biomarkers for diagnosis of hepatitis B-related hepatocellular carcinoma","volume":"554","author":"Zhang","year":"2024","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2026.104149_bb0575","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/1940-6207.CAPR-23-0311","article-title":"Combination of an autoantibody panel and alpha-fetoprotein for early detection of hepatitis B virus-associated hepatocellular carcinoma","volume":"17","author":"Shen","year":"2024","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0580","first-page":"253","article-title":"Paraneoplastic anti-Tif1-gamma autoantibody-positive dermatomyositis as clinical presentation of hepatocellular carcinoma recurrence","volume":"11","author":"Ferronato","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.autrev.2026.104149_bb0585","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1038\/s41598-024-70595-0","article-title":"Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma","volume":"14","author":"Kajornsrichon","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104149_bb0590","doi-asserted-by":"crossref","first-page":"24828","DOI":"10.18632\/oncotarget.15192","article-title":"Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma","volume":"8","author":"Ying","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.autrev.2026.104149_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129864","article-title":"The role of H2-Calponin antigen in Cancer metastasis: presence of autoantibodies in liver Cancer patients","volume":"24","author":"Bin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0600","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/ijc.33165","article-title":"Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: a prospective multicenter study","volume":"147","author":"Okada","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0605","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/labmed\/lmaa006","article-title":"Detection of circulating antibodies to p16 protein-derived peptides in hepatocellular carcinoma","volume":"51","author":"Xu","year":"2020","journal-title":"Lab Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0610","first-page":"83","article-title":"Immune checkpoint inhibitor-induced hepatic injury: a Clinicopathologic review","volume":"2","author":"Taherian","year":"2022","journal-title":"J Clin Transl Pathol"},{"key":"10.1016\/j.autrev.2026.104149_bb0615","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Nilasha","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0620","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/cei\/uxad036","article-title":"Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy","volume":"212","author":"Hsu","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0625","first-page":"37","article-title":"Interleukin-7 risk allele, lymphocyte counts, and autoantibodies for prediction of risk of immune-related adverse events in patients receiving atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma","volume":"103","author":"Takada","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.autrev.2026.104149_bb0630","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hepr.13969","article-title":"Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma","volume":"54","author":"Takada","year":"2024","journal-title":"Hepatol Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0635","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.gastha.2024.07.018","article-title":"Anti-PD-1 autoantibody predicts survival of patients with hepatocellular carcinoma receiving atezolizumab\/bevacizumab","volume":"3","author":"Sasaki","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.autrev.2026.104149_bb0640","doi-asserted-by":"crossref","first-page":"2351255","DOI":"10.1080\/2162402X.2024.2351255","article-title":"Distinct autoantibody profiles across checkpoint inhibitor types and toxicities","volume":"13","author":"Mu-Mosley","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2026.104149_bb0645","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053363","article-title":"Polyendocrine autoimmunity and diabetic ketoacidosis following anti-PD-1 and interferon \u03b1","volume":"149","author":"Dasgupta","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.autrev.2026.104149_bb0650","article-title":"Case report: a case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0655","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0660","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12328-020-01107-6","article-title":"Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma","volume":"13","author":"Suoh","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104149_bb0665","doi-asserted-by":"crossref","first-page":"1251134","DOI":"10.3389\/fimmu.2023.1251134","article-title":"Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids","volume":"14","author":"Kersten","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0670","doi-asserted-by":"crossref","first-page":"142","DOI":"10.15403\/jgld-1849","article-title":"Complete remission of advanced hepatocellular carcinoma treated with Sorafenib and concomitant appearance of IgG4- related diseases. A case report","volume":"30","author":"Impellizzeri","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.autrev.2026.104149_bb0675","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1593\/neo.10238","article-title":"Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker","volume":"12","author":"Defresne","year":"2010","journal-title":"Neoplasia (New York, NY)"},{"key":"10.1016\/j.autrev.2026.104149_bb0680","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.it.2020.03.006","article-title":"Noncanonical functions of antibodies","volume":"41","author":"Dimitrov","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0685","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3748\/wjg.v24.i17.1839","article-title":"Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma","volume":"24","author":"Mukaida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104149_bb0690","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13578-025-01432-8","article-title":"The human testis-specific protein Y-linked (TSPY) is a male-specific cancer-testis antigen capable of eliciting significant immune responses and elimination of positive tumor cells in hepatocellular carcinoma","volume":"15","author":"Kido","year":"2025","journal-title":"Cell Biosci"},{"key":"10.1016\/j.autrev.2026.104149_bb0695","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207344119","article-title":"ACBP\/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis","volume":"119","author":"Moti\u00f1o","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104149_bb0700","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ymthe.2020.11.017","article-title":"Selective depletion of antigen-specific antibodies for the treatment of demyelinating disease","volume":"29","author":"Sun","year":"2021","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.autrev.2026.104149_bb0705","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.191.4.625","article-title":"Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma","volume":"191","author":"J\u00e4ger","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0710","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0715","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/CIRCULATIONAHA.116.025446","article-title":"Emerging affinity-based proteomic Technologies for Large-Scale Plasma Profiling in cardiovascular disease","volume":"135","author":"Smith","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2026.104149_bb0720","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104149_bb0725","series-title":"Tumor-Associated Antigens","first-page":"45","article-title":"Humoral immune responses against Cancer antigens: Serological identification methods. Part I: SEREX","author":"Zwick","year":"2009"},{"key":"10.1016\/j.autrev.2026.104149_bb0730","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1074\/mcp.R600016-MCP200","article-title":"Cancer immunomics using autoantibody signatures for biomarker discovery","volume":"6","author":"Caron","year":"2007","journal-title":"Mol Cell Proteomics MCP"},{"key":"10.1016\/j.autrev.2026.104149_bb0735","first-page":"1315","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985"},{"key":"10.1016\/j.autrev.2026.104149_bb0740","doi-asserted-by":"crossref","first-page":"1599764","DOI":"10.3389\/fimmu.2025.1599764","article-title":"Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0745","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12967-024-05159-x","article-title":"Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology","volume":"22","author":"Lin","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0750","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/HEP.0000000000001046","article-title":"Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis","volume":"82","author":"Hsu","year":"2025","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.autrev.2026.104149_bb0755","article-title":"Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"4","author":"Do","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0760","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gutjnl-2024-334681","article-title":"Beneficial infections of the enterovirus genus in patients with liver cancer","volume":"74","author":"Ma","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104149_bb0765","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa0698","article-title":"Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome","volume":"348","author":"Xu","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.autrev.2026.104149_bb0770","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2020.05.038","article-title":"A viral exposure signature defines early onset of hepatocellular carcinoma","volume":"182","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104149_bb0775","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nbt.1856","article-title":"Autoantigen discovery with a synthetic human peptidome","volume":"29","author":"Larman","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2026.104149_bb0780","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cas.14732","article-title":"Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer","volume":"112","author":"Ma","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0785","article-title":"Serological biomarkers for early detection of hepatocellular carcinoma: a focus on autoantibodies against tumor-associated antigens encoded by Cancer driver genes","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.autrev.2026.104149_bb0790","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jprot.2009.02.006","article-title":"Protein arrays as tools for serum autoantibody marker discovery in cancer","volume":"72","author":"Kijanka","year":"2009","journal-title":"J Proteomics"},{"key":"10.1016\/j.autrev.2026.104149_bb0795","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-60327-047-2_12","article-title":"The \u201creverse capture\u201d autoantibody microarray: an innovative approach to profiling the autoantibody response to tissue-derived native antigens","volume":"441","author":"Ehrlich","year":"2008","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"10.1016\/j.autrev.2026.104149_bb0800","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1158\/1055-9965.EPI-13-0621","article-title":"Serologic autoantibodies as diagnostic Cancer biomarkers\u2014a review","volume":"22","author":"Zaenker","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2026.104149_bb0805","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/1615-9861(200107)1:7<890::AID-PROT890>3.0.CO;2-Z","article-title":"Identification of tumor antigens in renal cell carcinoma by serological proteome analysis","volume":"1","author":"Klade","year":"2001","journal-title":"Proteomics"},{"key":"10.1016\/j.autrev.2026.104149_bb0810","series-title":"Tumor-Associated Antigens","first-page":"63","article-title":"Humoral immune responses against Cancer antigens: Serological identification methods. Part II: Proteomex and AMIDA","author":"Seliger","year":"2009"},{"key":"10.1016\/j.autrev.2026.104149_bb0815","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2007.01.002","article-title":"High throughput proteomic strategies for identifying tumour-associated antigens","volume":"249","author":"Gunawardana","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2026.104149_bb0820","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1196\/annals.1381.024","article-title":"Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling","volume":"1107","author":"Hardouin","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0825","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/ac049068d","article-title":"Microfluidic chip for peptide analysis with an integrated HPLC column, sample enrichment column, and nanoelectrospray tip","volume":"77","author":"Yin","year":"2005","journal-title":"Anal Chem"},{"key":"10.1016\/j.autrev.2026.104149_bb0830","article-title":"High-throughput identification of autoantibodies that target the human exoproteome","volume":"2","author":"Wang","year":"2022","journal-title":"Cell Rep Meth"},{"key":"10.1016\/j.autrev.2026.104149_bb0835","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jss.2019.01.008","article-title":"SELDI-TOF MS analysis of hepatocellular carcinoma in an Australian cohort","volume":"238","author":"Schlichtemeier","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0840","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1039\/C8AN02241K","article-title":"MALDI-TOF MS-based total serum protein fingerprinting for liver cancer diagnosis","volume":"144","author":"Park","year":"2019","journal-title":"Analyst"},{"key":"10.1016\/j.autrev.2026.104149_bb0845","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41565-025-01918-z","article-title":"Nanopore-based enzyme-linked immunosorbent assay for cancer biomarker detection","volume":"20","author":"Yi","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.autrev.2026.104149_bb0850","first-page":"152","article-title":"\u0391-Enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis","volume":"20","author":"Zhang","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.autrev.2026.104149_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249718","article-title":"Cyclic peptide Mimotopes for the detection of serum anti-ATIC autoantibody biomarker in Hepato-cellular carcinoma","volume":"21","author":"Heo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104149_bb0860","first-page":"348","article-title":"A case of young hepatocellular carcinoma with non-B, non-C, non-cirrhotic background","volume":"118","author":"Hashimoto","year":"2021","journal-title":"Nihon Shokakibyo Gakkai zasshi"},{"key":"10.1016\/j.autrev.2026.104149_bb0865","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12916-025-04066-2","article-title":"Machine learning technique-based four-autoantibody test for early detection of esophageal squamous cell carcinoma: a multicenter, retrospective study with a nested case\u2013control study","volume":"23","author":"Xu","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0870","doi-asserted-by":"crossref","first-page":"A1602","DOI":"10.1016\/j.chest.2022.08.1345","article-title":"Impact of the NODIFY biomarker panel for risk stratification of pulmonary nodules at an academic medical center","volume":"162","author":"Ray","year":"2022","journal-title":"CHEST"},{"key":"10.1016\/j.autrev.2026.104149_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.chpulm.2024.100130","article-title":"Validation of a high-specificity blood autoantibody test to detect lung Cancer in pulmonary nodules","volume":"3","author":"Long","year":"2025","journal-title":"CHEST Pulmonary"},{"key":"10.1016\/j.autrev.2026.104149_bb0880","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061640","article-title":"Mucins as potential biomarkers for early detection of Cancer","volume":"15","author":"Gautam","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.autrev.2026.104149_bb0885","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104149_bb0890","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/nnm.13.20","article-title":"Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma","volume":"9","author":"Gao","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.autrev.2026.104149_bb0895","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104149_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1461041","article-title":"Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?","volume":"16","author":"Bridge","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119748","article-title":"Autoantibodies against Endophilin A2 as a novel biomarker are beneficial to early diagnosis of breast cancer","volume":"560","author":"Li","year":"2024","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2026.104149_bb0910","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13046-023-02867-y","article-title":"Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma","volume":"42","author":"Son","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.autrev.2026.104149_bb0915","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/JHC.S352057","article-title":"Autoantibody against ferritin light chain is a serum biomarker for the detection of liver cirrhosis but not liver cancer","volume":"9","author":"Ren","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.autrev.2026.104149_bb0920","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-020-00918-x","article-title":"Autoantibody signature in hepatocellular carcinoma using seromics","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2026.104149_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1647809","article-title":"Anti-OLA1 autoantibody is a potential early diagnostic marker for hepatocellular carcinoma","volume":"16","author":"Xiong","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104149_bb0930","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41416-025-03215-x","article-title":"A nomogram based on autoantibodies for noninvasive detection of AFP-negative hepatocellular carcinoma: a multicenter study","volume":"133","author":"Wang","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2026.104149_bb0935","first-page":"577","article-title":"Etudes sur la spermotoxine","volume":"14","author":"Metalnikoff","year":"1900","journal-title":"Ann Inst Pasteur"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:01:53Z","timestamp":1792857713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":187,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1568997226001631"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104149","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding tumor\u2013associated autoantibodies in liver cancer: Mechanisms, clinical applications, and detection methods","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104149"}}